Celltrion Achieves Strong Growth in Key Biosimilars in Australia and New Zealand
Strengthening Market Influence in Oceania
Celltrion's oncology and autoimmune disease products, currently being sold in Australia and New Zealand, continue to expand their market share, thereby strengthening the company's market influence in the Oceania region.
According to pharmaceutical market research agency IQVIA, as of the third quarter of last year, Celltrion's biosimilar for breast and gastric cancer treatment, Hyrzuma (ingredient: trastuzumab), achieved a dominant 56% market share in Australia, recording more than half of all prescriptions. Notably, in Australia, six different trastuzumab products, including the original, are fiercely competing. Among them, Hyrzuma captured a market share exceeding the combined share of all other products, drawing significant local attention.
Celltrion's biosimilar for breast cancer and gastric cancer treatment, Herzuma. Celltrion
View original imageStrong prescription performance continues in Celltrion's autoimmune disease portfolio as well. The company's flagship products, Remsima (ingredient: infliximab) and Remsima SC (subcutaneous formulation), together hold a combined 58% market share in Australia, outperforming competing products. In particular, since the launch of Remsima SC in Australia in 2021, its market share has risen from 5% in 2022 to 29% as of the third quarter of last year, reflecting an average annual growth rate of approximately 80%. Additionally, Stekima (ingredient: ustekinumab), a high-margin new product, achieved a 12% market share within a single quarter of its launch, demonstrating rapid growth.
These results are based on the customized sales and marketing strategies of Celltrion's local subsidiary, which are tailored to the unique characteristics of the Australian pharmaceutical market. Celltrion Australia has raised product awareness and prescription preference through proactive business activities, including participation in local academic societies and seminars for healthcare professionals, promotion of new clinical data, and strengthening networks with key stakeholders. The company has also continuously collaborated with major hospitals and pharmacy staff to establish a stable product supply chain, further contributing to the expansion of prescriptions.
Moreover, the implementation of biosimilar-friendly policies has also positively contributed to the increase in prescriptions for Celltrion's products. In Australia, when a patient is prescribed a specific original medicine for the first time, the physician is required to seek separate approval (Authority Required) under the Pharmaceutical Benefits Scheme (PBS), which involves a certain lead time. In contrast, biosimilars can use a simplified prescription code, making the approval process more streamlined and faster. This institutional difference increases the convenience of prescriptions for healthcare professionals and creates a favorable environment for the adoption of biosimilars.
Celltrion Australia is actively promoting this prescription convenience to local healthcare professionals. At the same time, the company operates patient-centered support systems, such as providing welcome kits, offering product information, and running injection training programs, to further enhance treatment convenience for both healthcare professionals and patients. This differentiated service strategy has strengthened brand trust, serving as a key driver for the early market establishment and expanded prescription of Celltrion's products.
Not only in Australia but also in neighboring New Zealand, Celltrion's oncology portfolio is demonstrating remarkable prescription results and steady progress. Hyrzuma has virtually dominated the trastuzumab market in New Zealand, with a market share close to 100%, while Vegzelma (ingredient: bevacizumab) maintains a competitive edge with an 81% market share. This success is mainly attributed to Celltrion New Zealand's smooth communication with the government tender agency Pharmac, which has enabled the company to continuously win bids and expand its market share.
In addition to its existing autoimmune disease portfolio, including Remsima SC and Stekima, Celltrion plans to further strengthen its marketing synergy by sequentially launching high-margin new products such as Stovoklo-Osenbelt (ingredient: denosumab) in the future. With its increasingly diversified portfolio, the company intends to expand its sales activities targeting physicians and healthcare institutions, while leveraging the brand trust established by existing products to ensure the early market adoption of its follow-up products as well.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kim Jitae, Head of South Asia at Celltrion, stated, "With the steady growth in prescriptions for all major products in both Australia and New Zealand, Celltrion's position in the Oceania market is being further strengthened. We will do our utmost to continue improving patient access to healthcare and achieve sustainable growth through tailored sales strategies that take into account the characteristics of local pharmaceutical markets and institutional environments, as well as by reinforcing our marketing capabilities based on our expanded product portfolio."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.